Compare PDC & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PDC | CTSO |
|---|---|---|
| Founded | 2018 | 1997 |
| Country | Japan | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.2M | 23.9M |
| IPO Year | 2022 | 2008 |
| Metric | PDC | CTSO |
|---|---|---|
| Price | $3.30 | $4.50 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $5.38 |
| AVG Volume (30 Days) | 33.3K | ★ 336.2K |
| Earning Date | 07-01-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 65.79 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $22,503,908.00 |
| Revenue This Year | N/A | $10.34 |
| Revenue Next Year | N/A | $22.41 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 48.53 |
| 52 Week Low | $2.42 | $0.30 |
| 52 Week High | $8.40 | $7.44 |
| Indicator | PDC | CTSO |
|---|---|---|
| Relative Strength Index (RSI) | 48.25 | 58.40 |
| Support Level | $2.64 | $0.47 |
| Resistance Level | $3.64 | $7.44 |
| Average True Range (ATR) | 0.44 | 0.58 |
| MACD | 0.08 | -0.20 |
| Stochastic Oscillator | 34.74 | 12.57 |
Perpetuals.com Ltd is a financial technology company bridging traditional financial markets with blockchain-based infrastructure. The group operates regulated financial market infrastructure at the intersection of traditional finance and digital assets. Its B2B offerings include capital markets technology delivered as SaaS and institutional-grade custody through Crypto Vault. For consumers, it provides compliant retail trading and prediction market platforms. The group's operations across the USA, Europe, and Asia develop software solutions that enable regulated trading venues to operate with 24/7 self-clearing and blockchain-based settlement technology, empowering institutions to compete in the evolving landscape of digital finance.
CytoSorbents Corp is a leader in blood purification for the treatment of life-threatening conditions in the intensive care unit and cardiac surgery. CytoSorbent's proprietary blood purification technologies are based on biocompatible, high-porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. CytoSorbent's technologies are used in several broad applications. Specifically, two important applications are: the removal of blood thinners during and after cardiothoracic surgery to reduce the risk of severe bleeding, and the removal of inflammatory agents and toxins in common critical illnesses that can cause massive inflammation, organ failure, and patient death. Geographically, in the USA, Germany, and Others.